First National Bank of South Miami Sells 830 Shares of VanEck Biotech ETF (NASDAQ:BBH)

First National Bank of South Miami lowered its stake in VanEck Biotech ETF (NASDAQ:BBH) by 34.2% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 1,598 shares of the company’s stock after selling 830 shares during the quarter. First National Bank of South Miami’s holdings in VanEck Biotech ETF were worth $249,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Miller Investment Management LP grew its holdings in VanEck Biotech ETF by 1,523.0% in the first quarter. Miller Investment Management LP now owns 107,492 shares of the company’s stock worth $17,423,000 after purchasing an additional 100,869 shares during the period. Morgan Stanley increased its position in VanEck Biotech ETF by 19.8% in the 4th quarter. Morgan Stanley now owns 74,987 shares of the company’s stock valued at $11,978,000 after buying an additional 12,375 shares in the last quarter. Citadel Advisors LLC acquired a new position in VanEck Biotech ETF during the 3rd quarter worth approximately $1,666,000. Aspen Grove Capital LLC bought a new position in VanEck Biotech ETF in the fourth quarter worth approximately $1,574,000. Finally, Chevy Chase Trust Holdings LLC acquired a new stake in VanEck Biotech ETF in the fourth quarter valued at approximately $1,396,000. Institutional investors and hedge funds own 36.23% of the company’s stock.

VanEck Biotech ETF Stock Performance

NASDAQ BBH opened at $159.04 on Tuesday. VanEck Biotech ETF has a 52 week low of $136.76 and a 52 week high of $170.25. The business has a 50 day moving average price of $160.92 and a 200-day moving average price of $159.97.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.